May 22 (Reuters) - The U.S. Food and Drug Administration's (FDA) staff on Wednesday pointed to "notable imbalance" in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk's
long-acting weekly insulin.
A panel of independent FDA advisers will meet on Friday to review and discuss the safety and effectiveness of Novo's insulin, icodec — an under-the-skin injection.
(Reporting by Mariam Sunny and Sriparna Roy in Bengaluru; Editing by Tasim Zahid and Shilpi Majumdar)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments